Compare KRP & AMLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KRP | AMLX |
|---|---|---|
| Founded | 2013 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.5B |
| IPO Year | 2017 | 2021 |
| Metric | KRP | AMLX |
|---|---|---|
| Price | $15.18 | $13.62 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 9 |
| Target Price | $17.33 | ★ $21.56 |
| AVG Volume (30 Days) | 949.4K | ★ 992.4K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | ★ 10.25% | N/A |
| EPS Growth | N/A | ★ 65.46 |
| EPS | N/A | ★ N/A |
| Revenue | $333,830,000.00 | ★ $380,786,000.00 |
| Revenue This Year | $6.88 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 7.93 | ★ 1612.94 |
| 52 Week Low | $11.31 | $4.64 |
| 52 Week High | $15.65 | $18.61 |
| Indicator | KRP | AMLX |
|---|---|---|
| Relative Strength Index (RSI) | 54.60 | 39.29 |
| Support Level | $14.10 | $13.36 |
| Resistance Level | $15.65 | $15.37 |
| Average True Range (ATR) | 0.32 | 0.79 |
| MACD | -0.01 | -0.17 |
| Stochastic Oscillator | 71.84 | 26.44 |
Kimbell Royalty Partners LP owns and acquires mineral and royalty interests in oil and natural gas properties throughout the United States. The company's basins and producing regions include areas of interest in the Permian Basin, Mid-Continent, Terryville/Cotton Valley/Haynesville, Appalachian Basin, Eagle Ford, Bakken/Williston Basin, and DJ Basin/Rockies/Niobrara. Its revenues are derived from royalty payments received from operators based on the sale of oil, natural gas and NGL production, as well as the sale of NGLs that are extracted from natural gas during processing.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.